Novo Nordisk A/S : Attractive timing with a long term view to go long again
Entry price | Target | Stop-loss | Potential |
---|
DKK 284.25 |
DKK 310 |
DKK 271.1 |
+9.06% |
---|
Technically, timing appears good within a medium term time horizon to buy shares in Novo Nordisk A/S. The technical support area at 273.35 DKK effectively limits downside risk and should allow the stock to get back into an upward dynamic.
Strengths● The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at DKK 273.35 DKK in weekly data.
● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● Based on current prices, the company has particularly high valuation levels.
● The underlying tendency is negative on the weekly chart below the resistance at 302.4 DKK
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
Surperformance is Buy on NOVO NORDISK A/S since 2023-09-13
.